ANNJI PHARM CO LTD has a total of 41 patent applications. Its first patent ever was published in 2013. It filed its patents most often in China, EPO (European Patent Office) and Republic of Korea. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are N30 PHARMACEUTICALS LLC, N30 PHARMACEUTICALS INC and FREYNE EDDY JEAN EDGARD.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 5 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | Republic of Korea | 5 | |
#4 | United States | 5 | |
#5 | WIPO (World Intellectual Property Organization) | 5 | |
#6 | Israel | 4 | |
#7 | Brazil | 3 | |
#8 | India | 3 | |
#9 | Russian Federation | 3 | |
#10 | Canada | 1 | |
#11 | Mexico | 1 | |
#12 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Chern Ji-Wang | 19 |
#2 | Chang Pei-Teh | 11 |
#3 | Chern Ji Wang | 9 |
#4 | Yu Chao-Wu | 8 |
#5 | Chang Pei Teh | 6 |
#6 | Talekar Rahul Subhash | 5 |
#7 | Chen Grace Shiahuy | 5 |
#8 | Jagtap Ajit Dhananjay | 5 |
#9 | Liu Jia-Rong | 4 |
#10 | Lai Shin-Yu | 4 |
Publication | Filing date | Title |
---|---|---|
MX2019013333A | Histone deacetylases (hdacs) inhibitors. | |
KR20150005630A | Cyclopropanecarboxylate esters of purine analogues | |
KR20150136070A | Multifunctional quinoline derivatives as anti-neurodegenerative agents | |
KR20150000901A | Histone deacetylases(hdacs) inhibitors | |
US2014296251A1 | Multifunctional quinoline derivatives as anti-neurodegenerative agents |